Use and abuse of taxanes in the management of metastatic breast cancer

被引：15

作者：

Bernard-Marty, C ^{[1
]}

Cardoso, F ^{[1
]}

Piccart, MJ ^{[1
]}

机构：

[1] Inst Jules Bordet, Dept Med Oncol, B-1000 Brussels, Belgium

来源：

EUROPEAN JOURNAL OF CANCER | 2003年 / 39卷 / 14期

关键词：

D O I：

10.1016/S0959-8049(03)00538-0

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Taxanes are currently introduced early in the treatment of patients with metastatic breast cancer (MBC), both as single agents and in combination with anthracyclines. Two different patient populations exist: those with no or minimal prior anthracycline exposure and those who have failed previous anthracyclines. The data generated through phase III trials in first-line MBC therapy will be reviewed and their interpretation for routine clinical practice (use versus abuse) will be discussed. Ways of improving taxane-based treatment tailoring both in the pre- and postgenomic eras will be addressed. (C) 2003 Elsevier Ltd. All rights reserved.

引用

页码：1978 / 1989

页数：12

共 40 条

[1] [Anonymous], 2002, P AM SOC CLIN ONCOL
[2] [Anonymous], P AM SOC CLIN ONCOL
[3] BELLOT R, 1998, P AN M AM SOC CLIN, V17, pA221
[4] Bernard-Marty Chantal, 2002, Clin Breast Cancer, V3, P341, DOI 10.3816/CBC.2002.n.037
[5] Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: The European Organization for Research and Treatment of Cancer 10961 multicenter phase III trial
Biganzoli, L
Cufer, T
Bruning, P
Coleman, R
Duchateau, L
Calvert, AH
Gamucci, T
Twelves, C
Fargeot, P
Epelbaum, R
Lohrisch, C
Piccart, MJ
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (14) : 3114 - 3121
[6] Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer
Bishop, JF
Dewar, J
Toner, GC
Smith, J
Tattersall, MHN
Olver, IN
Ackland, S
Kennedy, I
Goldstein, D
Gurney, H
Walpole, E
Levi, J
Stephenson, J
Canetta, R
[J]. JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (08) : 2355 - 2364
[7] Docetaxel vs 5-fluorouracil plus vinorelbine in metastatic breast cancer after anthracycline therapy failure
Bonneterre, J
Roché, H
Monnier, A
Guastalla, JP
Namer, M
Fargeot, P
Assadourian, S
[J]. BRITISH JOURNAL OF CANCER, 2002, 87 (11) : 1210 - 1215
[8] CARMICHAEL J, 2001, P AN M AM SOC CLIN, V20, pA22
[9] Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer
Chan, S
Friedrichs, K
Noel, D
Pintér, T
Van Belle, S
Vorobiof, D
Duarte, R
Gil, MG
Bodrogi, I
Murray, E
Yelle, L
von Minckwitz, G
Korec, S
Simmonds, P
Buzzi, F
Mancha, RG
Richardson, G
Walpole, E
Ronzoni, M
Murawsky, M
Alakl, M
Riva, A
Crown, J
[J]. JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (08) : 2341 - 2354
[10] DILEO A, 2002, P AM SOC CLIN ONCOL, V21

← 1 2 3 4 →